We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Evaluates selective THRβ agonists' effectiveness in targeting MASH, indicating potential therapeutic advances.
is a promising candidate for the development of selective THRβ-targeted therapies for MASH.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: